Arax Advisory Partners’s Cytek Biosciences CTKB Stock Holding History

Arax Advisory Partners’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Buy	23,786 +23,565	+10,663%	+$101K	﹤0.01%	2690
2026 Q1	$1.67K	Buy	221 +209	+1,742%	+$987	﹤0.01%	3154
2025 Q4	$61	Sell	12 -30,247	-100%	-$140K	﹤0.01%	3891
2025 Q3	$105K	Buy	+30,259	New	+$114K	﹤0.01%	1522
2025 Q1	–	Sell	-187	Closed	-$1.21K	–	2752
2024 Q4	$1.21K	Buy	+187	New	+$1.11K	﹤0.01%	2127

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arax Advisory Partners's CTKB Position: Q2 2026 in Review

Arax Advisory Partners increased its Cytek Biosciences (CTKB) stake by 10,663% in Q2 2026, buying an estimated $101K and bringing the position to 23,786 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #2690.

Arax Advisory Partners first reported a position in CTKB in Q4 2024 and has held it in 5 quarters since. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Arax Advisory Partners held 23,786 shares of Cytek Biosciences worth $105K as of Q2 2026.
Arax Advisory Partners bought 23,565 Cytek Biosciences shares in Q2 2026, an estimated $101K.
Cytek Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2690 holding.
Arax Advisory Partners first reported a position in Cytek Biosciences in Q4 2024 and has held it in 5 quarters since.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.